Screener
Ligand Pharmaceuticals LGND Agenus Inc. — Financial Royalty Assets, Allowance
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsAllowance.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
| Line item | June 30, 2026 / Gross carrying value(1) | June 30, 2026 / Allowance | June 30, 2026 / Net carrying value (1) | December 31, 2025 / Gross carrying value(1) | December 31, 2025 / Allowance | December 31, 2025 / Net carrying value(1) |
|---|---|---|---|---|---|---|
| Qarziba | $101,303 | $(468) | $100,835 | $118,593 | $(498) | $118,095 |
| Agenus Bot/Bal | 40,815 | (408) | 40,407 | 40,815 | (408) | 40,407 |
| Tolerance Therapeutics (Tzield®) | 25,470 | (99) | 25,371 | 25,257 | (98) | 25,159 |
| Ohtuvayre inventors | 19,957 | (179) | 19,778 | 16,921 | (151) | 16,770 |
| Elutia (CorMatrix) | 6,062 | (837) | 5,225 | 6,607 | (1,107) | 5,500 |
| AT220 | 4,442 | (109) | 4,333 | 5,132 | (132) | 5,000 |
| Primrose mRNA | 3,281 | (98) | 3,183 | 3,281 | (98) | 3,183 |
| Zerion | 2,640 | (79) | 2,561 | — | — | — |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Ligand Pharmaceuticals's agenus inc. — financial royalty assets, allowance?
- Ligand Pharmaceuticals (LGND) reported agenus inc. — financial royalty assets, allowance of $408K in Q2 2026.
- What does agenus inc. — financial royalty assets, allowance mean?
- This metric represents the cumulative valuation adjustments, such as allowances for credit losses or impairment reserves, applied to the royalty assets linked to Agenus Inc. It reflects management's assessment of potential risks or declines in the expected future cash flows from these specific licensed products. A significant change in this allowance can signal shifts in the commercial outlook or credit risk profile of the underlying pharmaceutical programs.
Ask your AI about Ligand Pharmaceuticals's agenus inc. — financial royalty assets, allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude